Protalix BioTherapeutics, Inc. (PLX)
Automate Your Wheel Strategy on PLX
With Tiblio's Option Bot, you can configure your own wheel strategy including PLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PLX
- Rev/Share 0.7801
- Book/Share 0.5901
- PB 2.3725
- Debt/Equity 0.1158
- CurrentRatio 2.488
- ROIC 0.0688
- MktCap 111449940.0
- FreeCF/Share -0.0204
- PFCF -71.3508
- PE 27.4454
- Debt/Assets 0.0709
- DivYield 0
- ROE 0.1046
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Protalix eyes Phase II gout trial later this year following solid Q1 revenue growth
Published: May 09, 2025 by: Proactive Investors
Sentiment: Positive
Protalix Biotherapeutics Inc (NYSE-A:PLX) said it is on track to launch a Phase II clinical trial of its experimental gout treatment PRX-115 later this year, as the company builds on momentum from positive early-stage results and rising product sales. The Israeli biopharmaceutical firm reported first-quarter revenues from product sales of $10 million, up 170% from a year earlier, driven largely by higher sales to Pfizer and Brazil's Fiocruz.
Read More
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results
Published: May 09, 2025 by: PRNewsWire
Sentiment: Neutral
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2025, and provided a business and clinical update.
Read More
Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline
Published: April 10, 2025 by: Seeking Alpha
Sentiment: Positive
Protalix BioTherapeutics is rated a Strong Buy due to stable income, profitability, and potential from pipeline programs PRX-115 and PRX-119. Elelyso and Elfabrio provide recurring revenue, with increasing royalties expected, and the company has achieved a debt-free status and profitability. PRX-115 shows promise for gout treatment, potentially outperforming KRYSTEXXA, while PRX-119 targets NETs but remains speculative.
Read More
Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline - ICYMI
Published: March 21, 2025 by: Proactive Investors
Sentiment: Positive
Protalix Biotherapeutics Inc (NYSE-A:PLX) chairman Eliot Forster joined Proactive to discuss the company's unique approach to drug manufacturing using plant cells instead of mammalian cells. He explained that this method enhances purity, sustainability, and reproducibility, setting Protalix apart in the biotech space.
Read More
Protalix Biotherapeutics gains momentum: analysts see long-term upside
Published: March 18, 2025 by: Proactive Investors
Sentiment: Positive
Protalix Biotherapeutics Inc (NYSE-A:PLX) reported increased product revenues for 2024, driven by higher sales of its Fabry disease treatment, Elfabrio, to partner Chiesi Rare Disease. The company's improving financial position and revenue outlook have analysts projecting further upside following the release of its full year 2024 results.
Read More
Protalix Biotherapeutics poised for profitability as rare disease drug gains momentum
Published: February 24, 2025 by: Proactive Investors
Sentiment: Positive
For a small biotech company, Protalix Biotherapeutics Inc (NYSE-A:PLX) is making a big impression with analysts and investors by targeting rare diseases with cutting-edge treatments. The New Jersey- and Israel-based company has emerged as a biotech underdog with strong tailwinds that analysts at HC Wainwright and Zacks Small Cap Research believe puts it the brink of sustainable profitability.
Read More
About Protalix BioTherapeutics, Inc. (PLX)
- IPO Date 1998-05-15
- Website https://www.protalix.com
- Industry Biotechnology
- CEO Mr. Dror Bashan
- Employees 213